Your browser doesn't support javascript.
loading
Structural and mechanistic insights into the inhibition of respiratory syncytial virus polymerase by a non-nucleoside inhibitor.
Yu, Xiaodi; Abeywickrema, Pravien; Bonneux, Brecht; Behera, Ishani; Anson, Brandon; Jacoby, Edgar; Fung, Amy; Adhikary, Suraj; Bhaumik, Anusarka; Carbajo, Rodrigo J; De Bruyn, Suzanne; Miller, Robyn; Patrick, Aaron; Pham, Quyen; Piassek, Madison; Verheyen, Nick; Shareef, Afzaal; Sutto-Ortiz, Priscila; Ysebaert, Nina; Van Vlijmen, Herman; Jonckers, Tim H M; Herschke, Florence; McLellan, Jason S; Decroly, Etienne; Fearns, Rachel; Grosse, Sandrine; Roymans, Dirk; Sharma, Sujata; Rigaux, Peter; Jin, Zhinan.
Afiliación
  • Yu X; Johnson & Johnson Innovative Medicine, Spring House, Pennsylvania, PA, 19477, USA. xyu6@its.jnj.com.
  • Abeywickrema P; Johnson & Johnson Innovative Medicine, Spring House, Pennsylvania, PA, 19477, USA.
  • Bonneux B; Janssen Infectious Diseases and Vaccines, 2340, Beerse, Belgium.
  • Behera I; University of Antwerp, Antwerp, Belgium.
  • Anson B; Johnson & Johnson Innovative Medicine, Brisbane, CA, 94005, USA.
  • Jacoby E; Johnson & Johnson Innovative Medicine, Brisbane, CA, 94005, USA.
  • Fung A; Johnson & Johnson Innovative Medicine, Beerse, Belgium.
  • Adhikary S; Johnson & Johnson Innovative Medicine, Brisbane, CA, 94005, USA.
  • Bhaumik A; Johnson & Johnson Innovative Medicine, Spring House, Pennsylvania, PA, 19477, USA.
  • Carbajo RJ; Johnson & Johnson Innovative Medicine, Spring House, Pennsylvania, PA, 19477, USA.
  • De Bruyn S; Johnson & Johnson Innovative Medicine, Janssen-Cilag, Discovery Chemistry S.A. Río Jarama, 75A, 45007, Toledo, Spain.
  • Miller R; Janssen Infectious Diseases and Vaccines, 2340, Beerse, Belgium.
  • Patrick A; Johnson & Johnson Innovative Medicine, Spring House, Pennsylvania, PA, 19477, USA.
  • Pham Q; Johnson & Johnson Innovative Medicine, Spring House, Pennsylvania, PA, 19477, USA.
  • Piassek M; Johnson & Johnson Innovative Medicine, Brisbane, CA, 94005, USA.
  • Verheyen N; Johnson & Johnson Innovative Medicine, Spring House, Pennsylvania, PA, 19477, USA.
  • Shareef A; Janssen Infectious Diseases and Vaccines, 2340, Beerse, Belgium.
  • Sutto-Ortiz P; Department of Microbiology, National Emerging Infectious Diseases Laboratories, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 02118, USA.
  • Ysebaert N; Aix Marseille Université, CNRS, AFMB, UMR 7257, Marseille, France.
  • Van Vlijmen H; Janssen Infectious Diseases and Vaccines, 2340, Beerse, Belgium.
  • Jonckers THM; Johnson & Johnson Innovative Medicine, Beerse, Belgium.
  • Herschke F; Johnson & Johnson Innovative Medicine, Beerse, Belgium.
  • McLellan JS; Janssen Infectious Diseases and Vaccines, 2340, Beerse, Belgium.
  • Decroly E; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, 78712, USA.
  • Fearns R; Aix Marseille Université, CNRS, AFMB, UMR 7257, Marseille, France.
  • Grosse S; Department of Microbiology, National Emerging Infectious Diseases Laboratories, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 02118, USA.
  • Roymans D; Johnson & Johnson Innovative Medicine, Beerse, Belgium.
  • Sharma S; Janssen Infectious Diseases and Vaccines, 2340, Beerse, Belgium.
  • Rigaux P; Johnson & Johnson Innovative Medicine, Spring House, Pennsylvania, PA, 19477, USA.
  • Jin Z; Janssen Infectious Diseases and Vaccines, 2340, Beerse, Belgium.
Commun Biol ; 6(1): 1074, 2023 10 21.
Article en En | MEDLINE | ID: mdl-37865687
ABSTRACT
The respiratory syncytial virus polymerase complex, consisting of the polymerase (L) and phosphoprotein (P), catalyzes nucleotide polymerization, cap addition, and cap methylation via the RNA dependent RNA polymerase, capping, and Methyltransferase domains on L. Several nucleoside and non-nucleoside inhibitors have been reported to inhibit this polymerase complex, but the structural details of the exact inhibitor-polymerase interactions have been lacking. Here, we report a non-nucleoside inhibitor JNJ-8003 with sub-nanomolar inhibition potency in both antiviral and polymerase assays. Our 2.9 Å resolution cryo-EM structure revealed that JNJ-8003 binds to an induced-fit pocket on the capping domain, with multiple interactions consistent with its tight binding and resistance mutation profile. The minigenome and gel-based de novo RNA synthesis and primer extension assays demonstrated that JNJ-8003 inhibited nucleotide polymerization at the early stages of RNA transcription and replication. Our results support that JNJ-8003 binding modulates a functional interplay between the capping and RdRp domains, and this molecular insight could accelerate the design of broad-spectrum antiviral drugs.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Virus Sincitial Respiratorio Humano Idioma: En Revista: Commun Biol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Virus Sincitial Respiratorio Humano Idioma: En Revista: Commun Biol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos